Other medication classes used in diabetes

Finding from the PROCEED trial show that dietary salt restriction helps to reduce albuminuria in patients with type 2 diabetes taking losartan, the investigators report in The Lancet Diabetes & Endocrinology.

Results of AdDIT show that treatment with an ACE inhibitor, a statin, or both does not protect against the increased albumin excretion that frequently occurs in patients with type 1 diabetes during adolescence.

A prespecified analysis of the FOURIER trial shows that the PCSK9 inhibitor evolocumab is as beneficial in patients with diabetes as in those without.

The effect of the PCSK9 inhibitor alirocumab on dyslipidemia in patients with type 1 diabetes is consistent with that seen in the type 2 population, the ODYSSEY team has revealed.

An analysis in JAMA shows that the price of PCSK9 inhibitors, recently shown to be effective against diabetic dyslipidemia, will need to fall by nearly three-quarters before they can be considered cost-effective even in high-risk patients with established cardiovascular disease.

Here we provide an overview of the seven Cochrane reviews published in June that covered topics relating to diabetes, including glycemic control for prevention of renal failure, phototherapy for foot ulcers, and anti-vascular endothelial growth factor treatment for diabetic macular edema.

Data from the ODYSSEY series of trials, presented at the American Diabetes Association scientific sessions, show that the PCSK9 inhibitor alirocumab reduces atherogenic dyslipidemia in patients with diabetes.

Researchers find that the increased risk for type 2 diabetes among patients taking statins is limited to the least fit individuals.

Results of the CLARITY trial suggest that aflibercept treatment may produce better visual outcomes than laser photocoagulation in patients with proliferative diabetic retinopathy.

A substantial proportion of diabetes patients experience improvements in diabetic retinopathy while receiving anti-vascular endothelial growth factor treatment, shows the latest analysis from DRCR.net.

The authors of a meta-analysis report mostly weak evidence, short-term follow-up, and evidence of publication bias in studies of pain relief in patients with diabetic peripheral neuropathy.